Literature DB >> 28379891

Relationship between plasma plasminogen activator inhibitor-1 and hypertension in American Indians: findings from the Strong Heart Study.

Hao Peng1, Fawn Yeh, Giovanni de Simone, Lyle G Best, Elisa T Lee, Barbara V Howard, Jinying Zhao.   

Abstract

OBJECTIVES: Deficient plasminogen activator inhibitor-1 (PAI-1) prevented hypertension in mice. Plasma PAI-1 was associated with hypertension in cross-sectional analyses, but the prospective association of PAI-1 with incident hypertension in large epidemiological studies is scarce.
METHODS: Leveraging two longitudinal cohorts of American Indians in the Strong Heart Study (SHS, N = 1019) and the Strong Heart Family Study (SHFS, N = 1502), we examined the prospective association of plasma PAI-1 with incident hypertension by multivariate logistic regression, adjusting for age, sex, study site, smoking, drinking, dietary sodium, obesity, lipids, fasting glucose, kidney function, inflammation, and follow-up years. Family relatedness in the SHFS was accounted for using the GLIMMIX procedure. Plasma PAI-1 level at baseline was measured by immunoassay. All participants were free of hypertension, cardiovascular diseases, and chronic kidney disease at baseline.
RESULTS: A total of 305 and 258 participants, respectively, from the SHS (57 ± 7 years) and the SHFS (33 ± 13 years) developed incident hypertension during follow-up. In the SHS, higher level of log-transformed PAI-1 was associated with 1.35-fold increased risk of hypertension [odds ratio (OR) (95% confidence interval): 1.35 (1.06-1.72)]. Analysis using categorical PAI-1 (in tertiles) showed that participants in the highest tertile (≥58 ng/ml) had 63% increased risk for hypertension [OR = 1.63 (1.12-2.37)] compared with those in the lowest tertile (<33 ng/ml). This association was confirmed in the SHFS with similar effect sizes [OR = 1.41 (1.11-1.81) for log-transformed PAI-1; OR = 1.64 (1.08-2.50) for categorical PAI-1: ≥58 vs. <33 ng/ml].
CONCLUSION: A higher level of plasma PAI-1 is significantly associated with hypertension in American Indians, independent of established risk factors. The potential causality warrants further investigation.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28379891      PMCID: PMC5615403          DOI: 10.1097/HJH.0000000000001375

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  36 in total

1.  Multiple biomarkers and the risk of incident hypertension.

Authors:  Thomas J Wang; Philimon Gona; Martin G Larson; Daniel Levy; Emelia J Benjamin; Geoffrey H Tofler; Paul F Jacques; James B Meigs; Nader Rifai; Jacob Selhub; Sander J Robins; Christopher Newton-Cheh; Ramachandran S Vasan
Journal:  Hypertension       Date:  2007-01-22       Impact factor: 10.190

2.  The association of clot lysis time with total obesity is partly independent from the association of PAI-1 with central obesity in African adults.

Authors:  Philna Eksteen; Marlien Pieters; Zelda de Lange; Herculina S Kruger
Journal:  Thromb Res       Date:  2015-06-09       Impact factor: 3.944

3.  Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition.

Authors:  K Kaikita; A B Fogo; L Ma; J A Schoenhard; N J Brown; D E Vaughan
Journal:  Circulation       Date:  2001-08-14       Impact factor: 29.690

4.  Genetic deficiency of plasminogen activator inhibitor-1 promotes cardiac fibrosis in aged mice: involvement of constitutive transforming growth factor-beta signaling and endothelial-to-mesenchymal transition.

Authors:  Asish K Ghosh; William S Bradham; Linda A Gleaves; Bart De Taeye; Sheila B Murphy; Joseph W Covington; Douglas E Vaughan
Journal:  Circulation       Date:  2010-09-07       Impact factor: 29.690

5.  Alcohol intake and glycemia in American Indians: the strong heart study.

Authors:  Weiquan Lu; Kathleen A Jablonski; Helaine E Resnick; Arvind K Jain; Kristina L Jones; Adrienne M Gottlieb; Thomas K Welty; Elisa T Lee; Richard R Fabsitz; Barbara V Howard
Journal:  Metabolism       Date:  2003-02       Impact factor: 8.694

6.  Plasminogen activator inhibitor-1 antagonist TM5441 attenuates Nω-nitro-L-arginine methyl ester-induced hypertension and vascular senescence.

Authors:  Amanda E Boe; Mesut Eren; Sheila B Murphy; Christine E Kamide; Atsuhiko Ichimura; David Terry; Danielle McAnally; Layton H Smith; Toshio Miyata; Douglas E Vaughan
Journal:  Circulation       Date:  2013-10-03       Impact factor: 29.690

7.  The plasma levels of plasminogen activator inhibitor-1 in subjects with white coat hypertension.

Authors:  E Coban; M Ozdogan
Journal:  Int J Clin Pract       Date:  2004-06       Impact factor: 2.503

8.  Potential roles of plasminogen activator system in coronary vascular remodeling induced by long-term nitric oxide synthase inhibition.

Authors:  Koichi Kaikita; John A Schoenhard; Corrie A Painter; Robert T Ripley; Nancy J Brown; Agnes B Fogo; Douglas E Vaughan
Journal:  J Mol Cell Cardiol       Date:  2002-06       Impact factor: 5.000

9.  The Role of Hemostatic Factors in Atherosclerosis in Patients with Chronic Renal Disease.

Authors:  Manal Zahran; Fatma Mohammed Nasr; Amna Ahmed Metwaly; Noha El-Sheikh; Nevine Sherif Ali Khalil; Tarek Harba
Journal:  Electron Physician       Date:  2015-09-16

10.  2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Authors:  Giuseppe Mancia; Robert Fagard; Krzysztof Narkiewicz; Josep Redon; Alberto Zanchetti; Michael Böhm; Thierry Christiaens; Renata Cifkova; Guy De Backer; Anna Dominiczak; Maurizio Galderisi; Diederick E Grobbee; Tiny Jaarsma; Paulus Kirchhof; Sverre E Kjeldsen; Stéphane Laurent; Athanasios J Manolis; Peter M Nilsson; Luis Miguel Ruilope; Roland E Schmieder; Per Anton Sirnes; Peter Sleight; Margus Viigimaa; Bernard Waeber; Faiez Zannad; Josep Redon; Anna Dominiczak; Krzysztof Narkiewicz; Peter M Nilsson; Michel Burnier; Margus Viigimaa; Ettore Ambrosioni; Mark Caufield; Antonio Coca; Michael Hecht Olsen; Roland E Schmieder; Costas Tsioufis; Philippe van de Borne; Jose Luis Zamorano; Stephan Achenbach; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Veronica Dean; Christi Deaton; Cetin Erol; Robert Fagard; Roberto Ferrari; David Hasdai; Arno W Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Patrizio Lancellotti; Ales Linhart; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Per Anton Sirnes; Juan Luis Tamargo; Michal Tendera; Adam Torbicki; William Wijns; Stephan Windecker; Denis L Clement; Antonio Coca; Thierry C Gillebert; Michal Tendera; Enrico Agabiti Rosei; Ettore Ambrosioni; Stefan D Anker; Johann Bauersachs; Jana Brguljan Hitij; Mark Caulfield; Marc De Buyzere; Sabina De Geest; Geneviève Anne Derumeaux; Serap Erdine; Csaba Farsang; Christian Funck-Brentano; Vjekoslav Gerc; Giuseppe Germano; Stephan Gielen; Herman Haller; Arno W Hoes; Jens Jordan; Thomas Kahan; Michel Komajda; Dragan Lovic; Heiko Mahrholdt; Michael Hecht Olsen; Jan Ostergren; Gianfranco Parati; Joep Perk; Jorge Polonia; Bogdan A Popescu; Zeljko Reiner; Lars Rydén; Yuriy Sirenko; Alice Stanton; Harry Struijker-Boudier; Costas Tsioufis; Philippe van de Borne; Charalambos Vlachopoulos; Massimo Volpe; David A Wood
Journal:  Eur Heart J       Date:  2013-06-14       Impact factor: 29.983

View more
  7 in total

Review 1.  Contribution of RAGE axis activation to the association between metabolic syndrome and cancer.

Authors:  Ma Eugenia Garay-Sevilla; Armando Gomez-Ojeda; Ileana González; Claudia Luévano-Contreras; Armando Rojas
Journal:  Mol Cell Biochem       Date:  2021-01-04       Impact factor: 3.396

2.  Differential gene regulation in human small airway epithelial cells grown in monoculture versus coculture with human microvascular endothelial cells following multiwalled carbon nanotube exposure.

Authors:  Brandi N Snyder-Talkington; Chunlin Dong; Vincent Castranova; Yong Qian; Nancy L Guo
Journal:  Toxicol Rep       Date:  2019-05-28

Review 3.  An aberrant STAT pathway is central to COVID-19.

Authors:  Toshifumi Matsuyama; Shawn P Kubli; Steven K Yoshinaga; Klaus Pfeffer; Tak W Mak
Journal:  Cell Death Differ       Date:  2020-10-09       Impact factor: 15.828

4.  Proteomic Analysis of Longitudinal Changes in Blood Pressure.

Authors:  Yi-Ting Lin; Tove Fall; Ulf Hammar; Stefan Gustafsson; Erik Ingelsson; Johan Ärnlöv; Lars Lind; Gunnar Engström; Johan Sundström
Journal:  J Clin Med       Date:  2019-10-02       Impact factor: 4.241

Review 5.  Therapeutics targeting the fibrinolytic system.

Authors:  Haili Lin; Luning Xu; Shujuan Yu; Wanjin Hong; Mingdong Huang; Peng Xu
Journal:  Exp Mol Med       Date:  2020-03-09       Impact factor: 8.718

Review 6.  A Serpin With a Finger in Many PAIs: PAI-1's Central Function in Thromboinflammation and Cardiovascular Disease.

Authors:  Gael B Morrow; Claire S Whyte; Nicola J Mutch
Journal:  Front Cardiovasc Med       Date:  2021-04-16

7.  Pharmacological inhibition of PAI-1 alleviates cardiopulmonary pathologies induced by exposure to air pollutants PM2.5.

Authors:  Asish K Ghosh; Saul Soberanes; Elizabeth Lux; Meng Shang; Raul Piseaux Aillon; Mesut Eren; G R Scott Budinger; Toshio Miyata; Douglas E Vaughan
Journal:  Environ Pollut       Date:  2021-05-07       Impact factor: 8.071

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.